Pharvaris N.V. (PHVS)

$KALV or $PHVS : which HAE biotech is the more likely buyout candidate?

$KALV $NTLA $PHVS am not into NTLA but will give a look as NTLA will not get PDUFA till next year and not sure when PHVS is and not as easy to switch drugs if working for user and doctor!!

$KALV $PHVS $TAK yes love KALV and PHVS and check out ARQT as underrated but their psoriasis cream for skin projects 2 billion sales and foam for hairy areas amazing efficacy and have other skin help for another 500 million so doubling sales staff to counter shorts as they know most of retail has stop loss and use it all the time but they can see and we do not even know who shorts are. ARQT will sell if we cannot get price to 40 or 50 per share VERY

Citizens reiterated $KALV Market Outperform; $28 $PHVS $TAK PHAR IONS BCRX Here's what Citizens said in its note: https://x.com/Quantumup1/status/2044801671402860730?s=20

RBC Capital maintains Pharvaris $PHVS at Outperform and lowers the price target from $52 to https://marketsblock.com/stock-upgrades-and-downgrades/

RBC Capital⬇️the PT on $PHVS to $51 from $52, reiterated Outperform, and said: CHAPTER-3 Pivotal Topline In Focus For 3Q $KALV $BCRX IONS TAK RBC Capital added: We continue to believe that PHVS has a high quality asset in deucrictibant, where both IR and XR formulations could capture significant market share across the HAE treatment spectrum given strong efficacy, clean safety, and oral convenience that should help it differentiate from other more entrenched players. In the near term, investor interest in the 3Q26 topline for XR is increasingly in focus, where we believe that the drug can continue to demonstrate injectable-like efficacy (at least 70% attack rate reductions) and a clean safety profile, where success could catalyze 80% potential upside, and what we see as limited downside given the derisked acute on-demand use opportunity (-25%). PT to $51 from $52 on model adjustments.

$PHVS Q4 '25 Earnings Results & Recap Pharvaris plans to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first half of 2026 for the on-demand treatment of acute attacks of HAE.

$PHVS i think pharvaris has a good chance of success in upcoming ph3, but thoughts on investment upside at current market cap? @Night_Owl_Biotech --fdmc: $2.35B (at $30/sh) --cash: $300 million as of Dec 2025 --catalyst: 3Q 2026 topline data from the CHAPTER-3 pivotal Phase 3 study for the prophylactic treatment of HAE --combined pys estimates: $1-1.25B --predicted buyout on success: $3-4b

$BCRX here’s what I think is going on.. A banker Likely leaked that there is a contingent offer on the table based on the results of the $PHVS data that is coming due any day now someone miss reported and leaked this and hence the stock has run up

RBC Capital reiterated $BCRX Outperform; $13, and said:::Recent unconfirmed media reports ( Betaville, 3/16 ) that BCRX could potentially be a takeout target have likely contributed to recent stock increase. Updating our prior takeout analysis, we believe that even with shares +24% YTD, shares remain undervalued across all takeout scenarios ($12-$20/share) and as an independent company (PT $13). While we acknowledge upcoming 3Q26 data from oral HAE prophy competitor $PHVS could have some impact on BCRX, our survey work and KOL feedback suggests that Orladeyo is likely to still have a meaningful role within the treatment paradigm even upon PHVS success, and could see a growing role for BCRX's next-gen agent navenibart as well among the longer-acting prophy injectables. We still see some upside potential from here; increasing downside floor and upside potential scenarios ($7/$20).

$PHVS RSI: 43.51, MACD: -0.1831 Vol: 0.90, MA20: 27.05, MA50: 26.72 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

$PHVS Pharvaris reports results from study of patient experience during HAE attacks Pharvaris announced that results from a Pharvaris-sponsored non-interventional, mixed methods, real-world study assessing the patient experience during acute HAE attacks across alternative endpoints used in clinical studies have been published in Clinical Reviews in Allergy & Immunology. The study evaluated the patient experience with HAE attack manifestations, and what constitutes meaningful changes in those manifestations, to support the inclusion of meaningful endpoints in clinical studies for on-demand treatment, or ODT, of HAE attacks, such as RAPIDe-3. Although approved medicines exist for the on-demand treatment of HAE attacks, there have been no head-to-head studies of on-demand therapies, and cross-trial comparisons have been challenging due to lack of uniformity in study design. Additionally, generation of evidence related to the key symptoms experienced by people during HAE attacks, insights into the subsequent perception from patients as to what are clinically-meaningful changes in symptoms, validation of the content of various patient-reported outcome, or PRO, instruments to support the evaluation of those symptoms, and confirmation of patient understanding and interpretation of that content, all could help in the evaluation of on-demand therapies by regulators, payers, and the HAE community. This mixed methods study provides strong evidence that the PGI and AMRA instruments are reliable, valid, and sensitive tools for assessing PROs in HAE attacks. Within the PRO assessments, most concepts were considered important by participants. Qualitative interviews confirmed that even relatively small improvements could be meaningful, such as the moment an attack was no longer worsening, as captured by the endpoint of End of Progression. Consistency across all PRO assessments of attack manifestation and response assessment were seen; End of Progression was the first-in-time achieved endpoint, followed by symptom relief, then symptom resolution. Importantly, the median time to onset of initial symptom relief as measured as PGI-C rating of at least "a little better" aligned more closely with the timing of AMRA-3 greater than or equal to20% than with the timing of AMRA-3 greater than or equal to30%. These results informed the hierarchy of endpoints in the Phase 3 RAPIDe-3 trial of deucrictibant and may also inform future trials of ODTs for HAE attacks.

$PHVS Current Stock Price: $26.66 Contracts to trade: $25.0 PHVS Mar 20 2026 Call Entry: $0.65 Exit: $1.09 ROI: 68% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

$PHVS RSI: 59.25, MACD: 0.4183 Vol: 0.80, MA20: 27.28, MA50: 26.61 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

#SHOWTIME American Academy of Allergy Asthma and Immunology Meeting (February 27 - March 1) Scheduled to appear: $COGT, $DBV, $ENTA, $PHVS, $SPRY

$PHVS Oncology biotech where clinical readouts define valuation.

$PHVS They releasing mew data on Feb 27?

$BCRX $PHVS sure Pharvaris with no revenue more worth than BCRX

$KALV Info for the "no risk" longs on this board. Yes, the balance sheet and market adaption here look quite nice. But apart from $PHVS the upcoming $NTLA P3 results expected mid year pose a pretty big threat to any HAE comp out there. Data presented on November 8, 2025, showed that 31 of 32 patients (97%) were attack-free and long-term prophylaxis (LTP)-free at data cutoff. If they reproduce these results in P3 and Gene editing is accepted by the patient population, the on demand market will shrink significantly. I think thats reason for the giant short interest.

$PHVS is a clinical-stage biotech developing photodynamic therapies for cancer; its technology is novel but unproven at scale, representing a high-risk, high-reward investment.

$PHVS volume pick up right shoulder formation.. over 30 sends it. watch for head fake